LeonaBio Stock Faces Binary Event: ELAINE-3 Trial Holds Company's Entire Future
LeonaBio has no backup plan if its single pivotal trial fails. The ELAINE-3 study of lasofoxifene for treatment-resistant metastatic breast cancer represents the company's only advanced-stage program, creating catastrophic concentration risk for shareholders.
ViaNews Editorial Team (Markets)•